A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

NCT02783599 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Olaratumab
DRUG: Doxorubicin
RADIATION: External Beam Radiotherapy

Sponsor

Eli Lilly and Company